Abatacept
- IV / SubcutAbataceptOrencia
Mechanism of Action
- A fusion protein with the Fc fragment of human IgG1 linked to the extracellular domain of CTLA-4. Binds to CD80 / CD86 on antigen presenting cells and prevents binding by CD28 on T lymphocytes, resulting in lack of a costimulatory response and reduced T cell activation.
Clinical Use
- Indications
- Moderate to severe rheumatoid arthritis
- Severe juvenile idiopathic arthritis
- Psoriatic arthritis refractory to other DMARDs
Contraindications
- Not to be used concurrently with other biologic DMARDs.
- Adverse Effects
- Injection site reactions
- Infections (particuarly upper respiratory tract infection)
- Headache
- Dizziness
- Nausea / vomiting / diarrhoea
- Abdominal pain
- Mouth ulcers
- Hypertension
- LFT derangement